Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on September 24, 2025, as the lead plaintiff process has been reopened by the Court [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed against Spectrum Pharmaceuticals, and interested parties can join by contacting the law firm [3][5]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study, which involved the drug poziotinib for lung cancer treatment, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [6].

Core Insights - Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, which evaluates rocatinlimab, a T-cell rebalancing therapy targeting the OX40 receptor, for treating moderate to severe atopic dermatitis [1][2] Study Overview - The ASCEND study involves approximately 2,600 patients and assesses the long-term safety and efficacy of rocatinlimab administered at doses of 150 mg and 300 mg every four or eight weeks [2] - The primary endpoint focuses on the long-term safety of rocatinlimab, with a descriptive nature [3] - The study is part of the larger ROCKET Phase 3 clinical program, which includes eight studies aimed at establishing the safety and efficacy profile of rocatinlimab [8][7] Safety and Efficacy Findings - The most common treatment-emergent adverse events in adults included upper respiratory infections, aphthous ulcers, headache, influenza, cough, and rhinitis, with a low discontinuation rate due to adverse events [3][4] - The incidence of gastrointestinal ulceration events with rocatinlimab is less than 1 per 100 patient-years [4] - Secondary endpoints showed that patients who achieved a clinical response in previous trials reported continued therapeutic benefits after one year of treatment [5] Expert Commentary - Amgen's executive vice president highlighted the importance of understanding OX40 inhibition in addressing atopic dermatitis and emphasized the durability of rocatinlimab's response and long-term safety profile [6] - Kyowa Kirin's Chief Medical Officer noted that the results represent a significant milestone in understanding rocatinlimab's ongoing therapeutic benefits, with potential maintenance dosing every eight weeks [6] Future Plans - Amgen and Kyowa Kirin plan to present full results at an upcoming congress or in a peer-reviewed publication [6]

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for alleged misleading statements regarding its financial condition and ability to manage macroeconomic challenges during the Class Period from January 30, 2025, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Dow Inc. overstated its ability to handle macroeconomic and tariff-related challenges, which negatively impacted its business and financial condition [5]. - Specific allegations include the understatement of competitive pressures, softening global sales, and an oversupply of products in Dow's markets [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors in this case [4]. - The firm has a strong track record, having recovered hundreds of millions for investors and being ranked highly in securities class action settlements [4]. - Investors are advised to select qualified legal counsel and can join the class action by contacting the firm [4][6].

Core Insights - IDEAYA Biosciences and Hengrui Pharma presented initial data from Hengrui's Phase 1 clinical trial of IDE849, a DLL3-targeting TOP1 antibody drug conjugate, at the IASLC 2025 World Conference on Lung Cancer [1][2] Efficacy Data - The trial included 100 patients, with 87 having small-cell lung cancer (SCLC) and 13 with other neuroendocrine carcinomas (NEC) [2] - In the expansion phase, 71 evaluable SCLC patients showed an overall response rate (ORR) of 73.2% across all lines of therapy [3][4] - At the 2.4 mg/kg dose, the ORR was 80.0% in 2L SCLC and 73.7% across all lines of SCLC [4][10] - A median progression-free survival (PFS) of 6.7 months was observed across all lines of SCLC [10] Safety Profile - Among 100 patients treated, 48% experienced Grade 3 or higher treatment-related adverse events (TRAEs) [10] - The most common TRAEs included neutropenia (33% Gr>3) and white blood cell reduction (27% Gr>3) [10] - The treatment-related discontinuation rate was 2%, with no treatment-related deaths reported [10] Collaboration and Future Development - Hengrui Pharma granted IDEAYA an exclusive worldwide license to develop and commercialize IDE849 outside of Greater China [7] - IDEAYA aims to advance the global clinical development of IDE849 for SCLC, NETs, and other DLL3 upregulated solid tumors [2][7]

Group 1 - The Rosen Law Firm is reminding purchasers of Lineage, Inc. common stock about the September 30, 2025 lead plaintiff deadline related to the class action lawsuit following Lineage's July 2024 IPO [1][3] - Investors who purchased Lineage common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5] - The lawsuit claims that the registration statement issued during the IPO was misleading, failing to disclose significant issues such as weakening customer demand and unsustainable price increases [5] Group 2 - The lawsuit alleges that Lineage was experiencing stagnant or falling revenue, occupancy rates, and rent prices, contrary to the representations made in the registration statement [5] - The Rosen Law Firm has a strong track record in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Investors interested in joining the class action can find more information through the Rosen Law Firm's website or by contacting their representatives [3][6]

Core Viewpoint - Rosen Law Firm is reminding purchasers of XPLR Infrastructure, LP common units of a class action lawsuit with a lead plaintiff deadline of September 8, 2025, for those who bought units between September 27, 2023, and January 27, 2025 [1] Group 1: Class Action Details - Investors who purchased XPLR common units during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - Investors wishing to serve as lead plaintiff must file with the Court by September 8, 2025 [3] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that XPLR made false and misleading statements regarding its operations as a yieldco, including struggles to maintain operations and the unsustainability of its business model [5] - It is claimed that XPLR entered financing arrangements while downplaying risks, which ultimately led to a halt in cash distributions to investors [5] - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Allegations - The investigation is prompted by an article from The New York Times highlighting serious incidents of patient harm and below-average performance on key safety measures at Encompass Health's rehab hospitals [3] - Following the publication of the article, Encompass Health's stock price dropped by 10.3% on July 15, 2025 [3] Group 2: Class Action Details - Investors who purchased Encompass Health securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Luminar Technologies, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Luminar securities between March 20, 2025, and May 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Luminar's executives made false and misleading statements, including undisclosed conduct by CEO Austin Russell that could lead to his removal, adversely affecting the company's business and financial guidance [5]. - The negative public perception and news related to Russell could harm Luminar's brand relationships and competitive standing in the industry [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Luminar Technologies, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 22, 2025 [1] Group 1: Class Action Details - Investors who purchased Luminar securities between March 20, 2025, and May 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [3] - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that Luminar's executives made false and misleading statements and failed to disclose critical information regarding CEO Austin Russell's undisclosed conduct, which could lead to his removal [5] - The potential loss of Russell could adversely affect Luminar's business operations, including competition, R&D management, and customer relationships [5] - The lawsuit claims that Luminar had no reasonable basis for its financial guidance, and the public statements made by the defendants were materially false and misleading [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025, of the September 26, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Lockheed Martin securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 26, 2025 [3]. - The lawsuit alleges that Lockheed Martin made false and misleading statements regarding its internal controls and ability to meet contract commitments, which led to significant investor losses when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].